TG Therapeutics Inc (TGTX)

Return on equity (ROE)

Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020
Net income US$ in thousands 23,383 12,672 -198,335 -348,101 -279,381
Total stockholders’ equity US$ in thousands 222,364 160,502 58,587 237,153 519,350
ROE 10.52% 7.90% -338.53% -146.78% -53.79%

December 31, 2024 calculation

ROE = Net income ÷ Total stockholders’ equity
= $23,383K ÷ $222,364K
= 10.52%

TG Therapeutics Inc's return on equity (ROE) has shown significant fluctuations over the years. In December 2020, the ROE was -53.79%, indicating that the company's net income was insufficient to generate a positive return for shareholders. This negative trend worsened in December 2021, with an ROE of -146.78%, and further deteriorated in December 2022 to -338.53%. These consecutive years of negative ROE reflect the company's challenges in generating profit relative to shareholder equity.

However, the financial performance improved in December 2023, as the ROE turned positive at 7.90%. This shift suggests that the company began to effectively utilize its equity to generate profits for shareholders. By December 2024, the ROE further increased to 10.52%, indicating continued progress in efficiently utilizing shareholder equity to generate returns.

Overall, the trend in TG Therapeutics Inc's ROE indicates a period of financial struggle followed by a recovery and improvement in profitability through better utilization of equity. It is important for investors to monitor the company's future ROE performance to assess its long-term financial health and sustainability.